

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 9/127, 38/00, 45/00, 45/05, 47/00, 47/44, A01N 37/18		A1	(11) International Publication Number: WO 97/02016 (43) International Publication Date: 23 January 1997 (23.01.97)
(21) International Application Number: PCT/US96/11373		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 2 July 1996 (02.07.96)			
(30) Priority Data: 114458 5 July 1995 (05.07.95) IL			
(71) Applicant (<i>for all designated States except US</i>): YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; P.O. Box 95, 76100 Rehovot (IL).		Published <i>With international search report.</i>	
(72) Inventors; and			
(75) Inventors/Applicants (<i>for US only</i>): COHEN, Irin, R. [US/IL]; 11 Hankin Street, 76344 Rehovot (IL). ELIAS, Dana [IL/IL]; 57 Derech Yavne, 76344 Rehovot (IL). SHINITZKY, Meir [IL/IL]; 20 Derech Haganim, 46910 Kfar Shmaryahu (IL).			
(74) Agent: BROWDY, Roger, L.; Browdy and Neimark, P.L.L.C., Suite 300, 419 7th Street N.W., Washington, DC 20004 (US).			

(54) Title: PREPARATIONS AND METHODS FOR THE TREATMENT OF T CELL MEDIATED DISEASES

(57) Abstract

Metabolizable lipid emulsions, such as Intralipid and Lipofundin, are excellent vehicles for peptide therapy of autoimmune diseases and of other TH1 T cell mediated diseases or conditions, as it promotes a TH1 to TH2 cytokine shift. Such emulsions may be used in conjunction with an antigen recognized by inflammatory T cells associated with the pathogenesis of a T cell mediated disease or condition for the therapeutic treatment of such a condition.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LK	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LR	Sri Lanka	SK	Slovakia
CM	Cameroon	LT	Liberia	SN	Senegal
CN	China	LU	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LV	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Latvia	TG	Togo
DE	Germany	MD	Monaco	TJ	Tajikistan
DK	Denmark	MG	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	ML	Madagascar	UA	Ukraine
ES	Spain	MN	Mali	UG	Uganda
FI	Finland	MR	Mongolia	US	United States of America
FR	France		Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**PREPARATIONS AND METHODS FOR THE TREATMENT OF T CELL MEDIATED
DISEASES**

5

Field of the Invention

The present invention relates to vaccine therapy for T-cell mediated diseases, and in particular to therapeutic preparations comprising antigens recognized by T cells involved in the pathogenesis of T cell mediated diseases, such as autoimmune diseases, and a metabolizable lipid emulsion as a biologically active carrier.

Background of the Invention

15 Autoimmune disorders, e.g., insulin-dependent diabetes mellitus (IDDM or type I diabetes), multiple sclerosis, rheumatoid arthritis and thyroiditis, are characterized by reactivity of the immune system to an endogenous antigen, with consequent injury to tissues. These 20 immune responses to self-antigens are maintained by the persistent activation of self-reactive T lymphocytes.

T cells of the CD4 "helper" type have been divided into two groups by the characteristic cytokines they secrete when activated (Mosmann and Coffman, 1989). TH1 cells secrete 25 IL-2, which induces T cell proliferation, and cytokines such as IFN- γ , which mediate tissue inflammation. TH2 cells, in contrast, secrete IL-4 and IL-10. IL-4 helps T cells secrete antibodies of certain IgG isotypes and suppresses the production of TH1 inflammatory cytokines (Banchereau et al., 30 1994). IL-10 indirectly inhibits TH1 activation by affecting antigen-presentation and inflammatory cytokine production by macrophages (Moore et al., 1993). It is the TH1 cells which contribute to the pathogenesis of organ-specific autoimmune 35 diseases. TH1-type responses also appear to be involved in other T cell mediated diseases or conditions, such as contact dermatitis (Romagnani, 1994).

Peptides suitable for immunologically specific therapy of an autoimmune disease are peptides that are

5 recognized by T cells involved in the pathogenesis of the autoimmune disease. Each autoimmune disease will have its ideal peptide for use in therapy. A disease like multiple sclerosis involving T cells reactive to self-antigens such as
myelin basic protein (MBP) (Allegreta et al., 1990) will require a peptide of myelin basic protein for its therapy, as for example those described by Ota et al., 1990.

The present inventors have shown that autoimmune diseases such as type I diabetes mellitus may be treated by
10 administering a suitable peptide in an oil vehicle. NOD mice spontaneously develop type I diabetes caused by autoimmune T cells that attack the insulin-producing β cells of the islets. The autoimmune attack is associated with T-cell reactivity to a variety of self-antigens including a peptide of
15 the 60kDa heat shock protein (hsp 60) and peptides of glutamic acid decarboxylase (GAD). Thus, for example, spontaneous diabetes developing in the NOD/Lt strain of mice could be treated with a peptide designated p277 corresponding to positions 437-460 of the human hsp 60 sequence (PCT Patent
20 Publication No. WO90/10449; D. Elias and I.R. Cohen, Peptide therapy for diabetes in NOD mice, The Lancet 343:704-06, 1994); with variants of the p277 peptide in which one or both cysteine residues at positions 6 and/or 11 have been replaced by valine and/or the Thr residue at position 16 is replaced by Lys (see
25 PCT Publication WO96/19236) and with peptides designated p12 and p32 corresponding to positions 166-185 and 466-485, respectively, of the human hsp60 sequence. See Israel Patent Application No. 114,407 of the same applicant of the present application, filed on June 30, 1995. See also PCT
30 application No. PCT/US96..., filed July 1, 1996, claiming priority from said Israel application no. 114,407, the entire contents of which are hereby incorporated by reference.

Peptide therapy for treatment of IDDM using p12, p32, p277 or variants thereof, was found by the present inventors to be effective when the peptide was administered to mice subcutaneously (sc) in an oil vehicle such as an emulsion of mineral oil known as incomplete Freund's adjuvant (IFA). However, IFA as well as complete Freund's adjuvant (CFA; a

preparation of mineral oil containing various amounts of killed organisms of *Mycobacterium*) are not allowed for human use because the mineral oil is not metabolizable and cannot be degraded in the body. Therefore, it would be desirable to
5 discover an effective vehicle for peptide therapy that would be metabolizable.

Several fat emulsions have been in use for many years for intravenous nutrition of human patients. Two of the available commercial fat emulsions, known as Intralipid
10 ("Intralipid" is a registered trade mark of Kabi Pharmacia, Sweden, for a fat emulsion for intravenous nutrition, described in US Patent No. 3,169,094) and Lipofundin (a registered trade mark of B. Braun Melsungen, Germany) contain soybean oil as fat (100 or 200 g in 1,000 ml distilled water: 10% or 20%,
15 respectively). Egg-yolk phospholipids are used as emulsifiers in Intralipid (12g/l distilled water) and egg-yolk lecithin in Lipofundin (12g/l distilled water). Isotonicity results from the addition of glycerol (25g/l) both in Intralipid and in Lipofundin. These fat emulsions are quite stable and have been
20 used for intravenous nutrition of patients suffering from gastrointestinal or neurological disorders, which prevent them from receiving nutrition orally, and thus they receive the calories needed to sustain life. Usual daily doses are of up to 1 liter daily.

25 US Patents No. 4,073,943 issued on February 14, 1978 to Wretlind et al. and Re. 32,393 issued on May 29, 1990 as reissue patent of US No. 4,168,308 issued on September 18, 1979 to Wretlind et al., describe a carrier system for use in enhancing parenteral, particularly intravenous, administration.
30 of a pharmacologically active, oil-soluble agent, comprising a stable, oil-in-water emulsion containing a pharmacologically inert lipoid as a hydrophobic phase dispersed in a hydrophilic phase, said lipid being dispersed in the emulsion as finely divided particles having a mean particle size less than 1 micron to achieve rapid onset of an acceptable therapeutic effect, said carrier system being used with an effective dose of said pharmacologically active, oil-soluble agent predominantly dissolved in said lipoid at a fraction ratio

thereto in the hydrophobic phase, said therapeutic effect being attributable to said effective dose of the active agent. This carrier system is said to be suitable for administration of a water-insoluble or water-soluble, oil-soluble pharmacologically active agent that is predominantly dissolved in the lipid phase. Examples of such pharmacologically active agents are depressants, anaesthetics, analgesics, stimulants, spasmolytics, muscle relaxants, vasodepressants and diagnostic, e.g. X-ray contrast, agents. The carrier system is said to enhance the diagnostic or therapeutic effect of the agent with a rapid onset accompanied by a reduced incidence of injury to body tissues.

Intralipid has been proposed as a non-irritating vehicle for several adjuvants for use in vaccines such as, for example, 6-O-(2-tetradecylhexadecanoyl)- and 6-O-(3-hydroxy-2-docosylhexacosanoyl)-N-acetylmuramyl-L-alanyl-D-isoglutamine (Tsujimoto et al., 1986 and 1989), avridine (Woodard and Jasman, 1985), N,N-dioctadecyl-N',N'-bis(2-hydroxyethyl) propanediamine (CP-20,961) (German Patent Application No. DE 2945788; Anderson and Reynolds, 1979; Niblack et al., 1979). Kristiansen and Sparrman, 1983, have disclosed that the immunogenicity of hemagglutinin and neuraminidase in mice is markedly increased after adsorption onto lipid particles constituting Intralipid.

None of the above publications describe the use of Intralipid as a vehicle for peptides in the treatment of autoimmune diseases, nor has there been any disclosure that Intralipid could mediate a shift of the immune response from a TH1-type response to a TH2-type response.

30

Summary of the Invention

It has now been found, in accordance with the present invention, that metabolizable lipid emulsions, such as Intralipid and Lipofundin, can act as vehicles for peptide therapy of autoimmune diseases and of other TH1 T cell mediated diseases or conditions. It has been further found that this activity is associated with a TH1 to TH2 cytokine shift.

The present invention thus relates to a therapeutic preparation for the treatment of an autoimmune disease or other T cell mediated disease or condition, comprising a peptide or other antigen and a biologically active lipid carrier, wherein
5 the peptide or other antigen is one recognized by inflammatory T-cells associated with the pathogenesis of said disease or condition, and wherein the biologically active lipid carrier is a fat emulsion comprising 10-20% triglycerides of plant and/or animal origin, 1.2-2.4% phospholipids of plant and/or animal
10 origin, 2.25-4.5% osmo-regulator, 0-0.05% anti-oxidant, and sterile water to 100%.

The triglycerides and phospholipids of plant or animal origin may derive from any suitable vegetable oil, such as soybean oil, cottonseed oil, coconut oil or olive oil, or
15 from egg-yolk or bovine serum. Preferably, the triglycerides are derived from soybean oil and the phospholipids are derived from soybean or from egg-yolk. Preferably, the triglycerides/phospholipids weight ratio is about 8:1.

Any suitable osmo-regulator may be added to the fat emulsion, preferably glycerol, xylitol or sorbitol. The fat emulsion may optionally comprise an anti-oxidant, for example 0.05% tocopherol.

In one embodiment of the invention, the fat emulsion as defined above is processed by centrifugation, e.g. at
25 10,000g or higher, thus forming a small triglyceride-rich (about 90% triglycerides) layer on the top of a phospholipid-enriched aqueous dispersion containing about 1:1 triglycerides:phospholipids, and this latter aqueous dispersion is used as the lipid vehicle in the preparations of the
30 invention.

In one preferred embodiment of the invention, the preparation is for the treatment of insulin-dependent diabetes mellitus (IDDM) and comprises a peptide derived from the human heat shock protein 60 (hsp60) that is recognized by
35 inflammatory T-cells associated with the pathogenesis of IDDM, wherein said peptide is selected from the group of peptides appearing in the following Table 1:

TABLE 1

	<u>Peptides</u>	<u>Sequence ID No:</u>	<u>Amino acid sequence (one letter code)</u>
5	p3	1 (31-50)	KFGADARALMLQGV DLLADA
	p10	1 (136-155)	NPVEIRR GVM LAVDAVIAEL
	p11	1 (151-170)	VIAELKKQSKPVTTPEEIAQ
	p12	1 (166-185)	EEIAQVATISANGDKEIGNI
	p14	1 (195-214)	RKGVITVKDGKTLNDELEII
10	p18	1 (255-274)	QSIVPALEIANAHRKPLVIIA
	p20	1 (286-305)	LVLNRLKVGLQVVAVKAPGF
	p24	1 (346-365)	GEVIVTKDDAMLLKGKGDKA
	p29	1 (421-440)	VTDALNATRAAVEEGIVLGG
	p30	1 (436-455)	IVLGGGCALLRCIPALDSLTLT
15	p32	1 (466-485)	EIIKRTLKIPAMTIAKNAGV
	p35	1 (511-530)	VNMVEKGIIIDPTKVVRTALL
	p39	1 (343-366)	GKVG EVIVTKDDAM
	p277	1 (437-460)	VLGGGCALLRCIPALDSLTPANED
	p277 (Val ⁶)	* 2	VLGGGVALLRCIPALDSLTPANED
20	p277 (Val ¹¹)	** 3	VLGGGCALLRVIPALDSLTPANED
	p277 (Val ⁶ -Val ¹¹)	*** 4	VLGGGVALLRVIPALDSLTPANED

* 437-460 of SEQ ID NO: 1 with C-442 changed to V

** 437-460 of SEQ ID NO: 1 with C-447 changed to V

25 *** 437-460 of SEQ ID NO: 1 with C-442 and C-447 changed to V

The invention further relates to a method for therapy of a subject suffering from an autoimmune disease or other TH1 mediated disease or condition, which comprises administering to 30 said subject an effective amount of a therapeutic preparation according to the invention.

Brief Description of the Drawings

Fig. 1 shows anti-p277 antibody production in NOD 35 mice treated with the peptide p277(Val⁶-Val¹¹) in: (i) Intralipid or (ii) phosphate-buffered saline (PBS), as described in Example 2.

Fig. 2 shows TH2-dependent antibody isotypes induced in NOD mice by treatment with the peptide p277(Val⁶-Val¹¹) in Intralipid, as described in Example 3.

5 Figs. 3A-B show that p277(Val⁶-Val¹¹)/ Intralipid therapy induces in NOD mice a specific switch in the profile of cytokines produced by the T-cells reactive to the p277(Val⁶-Val¹¹) peptide, as described in Example 4. Fig. 3A shows that there is a reduction of TH1 (IL-2, IFN- γ) and elevation of TH2 (IL-4, IL-10) cytokines after treatment of the mice with 10 the p277(Val⁶-Val¹¹) peptide in Intralipid and incubation of the spleen cells with p277(Val⁶-Val¹¹); Fig. 3B shows that there is no change in the cytokines after treatment of the mice with the p277(Val⁶-Val¹¹) peptide in Intralipid and incubation 15 of the spleen cells with Con A.

Fig. 4 shows that spontaneous T-cell proliferative responses to p277(Val⁶-Val¹¹) is reduced after treatment with the p277(Val⁶-Val¹¹) peptide in Intralipid, as described in Example 5.

20 Fig. 5 shows that treatment of rats with myelin basic protein peptide p71-90 in Intralipid reduces the severity of experimental autoimmune encephalomyelitis (EAE), as described in Example 6.

25 Fig. 6 shows that treatment of rats with myelin basic protein peptide p71-90 in IFA reduces the severity of experimental autoimmune encephalomyelitis (EAE), as described in Example 6.

Detailed Description of the Invention

According to the present invention, it was found that 30 p277(Val⁶-Val¹¹)-peptide treatment, in an appropriate carrier, down-regulated the spontaneous T-cell proliferative responses to epitopes of both hsp60 and GAD and abolished the production of autoantibodies to hsp60, to GAD and to insulin. Arrest of the disease process was associated, not with T-cell tolerance 35 or anergy, but with a shift in the cytokines produced by the autoimmune T cells reactive to p277(Val⁶-Val¹¹) from a TH1-like profile (IL-2, IFN γ) to a TH2-like profile (IL-4, IL-10). The modulation was immunologically specific; the spontaneous T-cell

response of the treated mice to a bacterial hsp60 peptide remained in the TH1 mode. Thus, the diabetogenic process characterized by autoimmunity to several self antigens can be cured using one of the antigens, e.g., peptide p277(Val⁶-Val¹¹).
5

The association of p277(Val⁶-Val¹¹) therapy with a switch in reactivity to p277(Val⁶-Val¹¹) from T-cell proliferation to antibodies indicates that the therapeutic effect results from a shift in the predominant cytokines
10 produced by the autoimmune T cells in the treated mice. TH1 cells secrete IL-2, which induces T-cell proliferation, and cytokines such as IFN- γ , which mediate tissue inflammation, thereby contributing to the pathogenesis of the disease; TH2 cells, in contrast, secrete IL-4 and IL-10. IL-4 helps B cells
15 secrete antibodies of certain IgG isotypes and suppresses the production of TH1 inflammatory cytokines. IL-10 indirectly inhibits TH1 activation by affecting antigen-presentation and inflammatory cytokine production by macrophages. Thus, TH2 cells suppress TH1 activity (see Liblau et al., 1995). The
20 shift from TH1 to TH2-like behavior was supported by analysis of the isotypes of the antibodies produced before and after p277(Val⁶-Val¹¹) therapy.

The fact that the mechanism of the therapeutic effect of the peptide in a lipid vehicle treatment is shown, to involve
25 a TH1 \rightarrow TH2 cytokine shift, provides the possibility of using the TH1 \rightarrow TH2 shift as evidence that the treatment was effective and did induce a beneficial response. In other words, the TH1 \rightarrow TH2 shift can serve as a surrogate marker of the response to treatment. For example, the lack of the shift can
30 indicate a need for a second treatment. See Israel Patent Application No. 114,459 filed on July 5, 1995, and the corresponding PCT application filed on even date herewith, the entire contents of which are hereby incorporated herein by reference.

35 The lipid emulsions of the present invention, when used as a vaccine adjuvant with the antigenic substance to which the T cells involved in the disease or condition being treated are active, serve to mediate a shift from a TH1 T cell

response prior to treatment to a TH2 T cell response after treatment. This finding establishes that such lipid emulsions are tolerogenic biologically active carriers which can be used in vaccines for the treatment of any TH1 mediated disease or
5 condition. In such vaccines, the antigen provides the immunological specificity for a therapeutic effect while the biologically active carrier of the present invention provides the biological outcome, i.e., the TH1→TH2 shift. Because of the shift mediated by said biologically active carrier of the
10 present invention, diseases with a spectrum of autoreactivities can be turned off with a single antigen/carrier combination capable of inducing a T cell cytokine shift.

A preferred use in accordance with the present invention is in the treatment of organ-specific autoimmune
15 diseases which are mediated by TH1 cells. Such diseases include, but are not limited to, autoimmune diseases such as IDDM, rheumatoid arthritis, multiple sclerosis and thyroiditis. The peptide used in such treatment is an autoantigen peptide. Thus, for example, for IDDM the peptide is the above-mentioned
20 p277 peptide or the valine substituted analog p277(Val⁶-Val¹¹) ; for multiple sclerosis such peptide is derived from myelin basic protein; for thyroiditis the peptide is thought to be derived from thyroglobulin, and for rheumatoid arthritis the autoantigen can derive from *Mycobacterium* organisms, e.g.,
25 *Mycobacterium tuberculosis*.

It is not critical that the antigen be a peptide. Thus, for example, TH1-mediated allergic responses which result in skin sensitivity and inflammation, such as contact dermatitis, can be treated by a vaccine containing the
30 irritant antigen and a biologically active carrier in accordance with the present invention which will cause a shift in the cytokine response from a TH1-type to a TH2-type. Thus, while the patient will continue to have elevated antibody levels against the antigen, the inflammatory T cell response causing the skin irritation will be suppressed.

Accordingly, the tolerogenic biologically active carrier of the present invention may be used any time that it is desired to create tolerance for the antigen which the T

cells are attacking, i.e., any time that a vaccine is being used to restrict a T cell mediated condition, particularly a TH1 cell mediated condition. If it can be determined which antigen is activating the response in graft rejection or in
5 graft-versus-host disease, then the administration of such an antigen with a carrier in accordance with the present invention would be expected to facilitate the shift of the undesirable inflammatory TH1 response to a more desirable TH2 response, regardless of the overall complexity of the number of antigens
10 to which T cells are active in such condition.

To determine the T-cell secretion of cytokines following activation with peptides, lymphocytes from the peripheral blood of patients are tested in an *in vitro* activation assay. Peripheral blood lymphocytes are isolated
15 from whole heparinized blood on ficol-hypaque, and cultured with the test peptide(s) at concentrations of 5-50 µg/ml. The supernatants from the cultured T-cells are collected at different time points and tested for activity of various cytokines, by ELISA or bioassay(s).

20 Examples of fat emulsions that can be used in the preparations of the present invention include, but are not limited to, the commercially available Intralipid and Lipofundin for intravenous nutrition, and the fat emulsions described in the above-mentioned US Patents Nos. 3,169,096,
25 4,073,943 and 4,168,308, herein incorporated by reference in their entirety. However, the finding according to the present invention that these metabolizable lipids, administered previously for intravenous nutrition, may be used effectively as vehicles for therapy of T cell mediated diseases, is
30 completely unexpected. Similarly, the discovery that these preparations are tolerogenic biologically active carriers which mediate a TH1→TH2 shift is also totally unexpected.

The fat emulsions of the present invention are preferably used as freshly prepared or after storage in a
35 container which is not open to the atmospheric air. Prolonged storage of Intralipid, for example, while exposed to atmospheric air, causes a decrease in the pH and a corresponding decrease in the biological activity.

In one embodiment, the biologically active carrier of the invention is a fat emulsion comprising 10% soybean oil, 1.2% egg-yolk phospholipids, 2.5% glycerol and sterile water to complete 100 ml (Intralipid 10%). In another embodiment, the vehicle is a fat emulsion comprising 20% soybean oil, 2.4% egg-yolk phospholipids, 2.5% glycerol and sterile water to complete 100 ml.

In yet another embodiment, the vehicle is a fat emulsion comprising 5% soybean oil and another 5% triglycerides from animal origin, e.g. 5% medium chain triglycerides from butter, 1.2% egg-yolk lecithin, 2.5% glycerol and distilled water to complete 100 ml (Lipofundin 10%).

In one embodiment of the invention, the vehicle is a processed lipid emulsion obtained by centrifugation, e.g. at 10,000g or higher, of the original fat emulsion defined herein, whereby a small triglyceride-rich (about 90% triglycerides) is formed on the top of a phospholipid-enriched aqueous dispersion containing about 1:1 triglycerides:phospholipids. The two phases are separated and the phospholipid-rich aqueous dispersion is used as the vehicle.

The preparations of the invention may comprise one or more peptides. Thus, for example, for the treatment of IDDM, the preparation may comprise one or more of the peptides p12, p32, p277, p277(Val⁶), p277(Val¹¹), p277(Val⁶-Val¹¹), or any of the other peptides of Table 1. In one preferred embodiment, the preparation for the treatment of IDDM comprises a peptide p277 or p277(Val⁶-Val¹¹) and a fat emulsion comprising 10% soybean oil, 1.2% egg-yolk phospholipids, 2.5% glycerol and sterile water to complete 100 ml (Intralipid 10%).

The invention further relates to the use of a fat emulsion as defined herein or of a processed phospholipid-enriched aqueous dispersion prepared therefrom by centrifugation for the preparation of a therapeutic preparation comprising one or more peptides or other antigens and said fat emulsion or processed aqueous dispersion as a vehicle in the therapy of autoimmune diseases or other TH1 mediated diseases or conditions.

The invention will now be illustrated by the following non-limiting examples.

EXAMPLES

5

Example 1.

Peptide therapy of type I diabetes using p277(Val⁶-Val¹¹) in oils

The efficacy of various lipid preparations as vehicles for peptide therapy of the diabetes of NOD mice was tested. In this model, autoimmune destruction of the insulin producing β -cells in the pancreas is mediated by T-lymphocytes. An inflammatory infiltrate develops around the pancreatic islets at 5-8 weeks of age and β -cell destruction leading to insulin deficiency and overt diabetes becomes manifested at 14-20 weeks of age affecting almost 100% of female NOD mice by 35-40 weeks of age.

NOD female mice were treated with 100 μ g of peptide p277(Val⁶-Val¹¹) per mouse sc in 0.1 ml of: (i) Phosphate-buffered saline (PBS), or (ii) a 10% lipid emulsion composed of 10% soybean oil, 1.2% egg phospholipids and 2.25% glycerol (Intralipid, Kabi Pharmacia AB, Sweden).

The incidence of diabetes at 6 months of age and the production of anti-p277(Val⁶-Val¹¹) antibodies was followed. Diabetes was diagnosed as persistent hyperglycemia, blood glucose levels over 11 mmol/L measured at least twice at weekly intervals with a Beckman Glucose Analyzer II. Successful peptide treatment was assayed by maintenance of a normal blood glucose concentration (less than 11 mmol/L), remission of the intra-islet inflammation of the pancreatic islets (insulitis) and induction of antibodies to the therapeutic peptide as an indicator of a TH2-type immune response. The results are shown in Table 2.

35

Table 2: Incidence of Diabetes at 6 months.

Treatment (%)	Diabetes	Death (%) incidence
5		
p277(Val ⁶ -Val ¹¹)/PBS	90	80
p277(Val ⁶ -Val ¹¹)/Intralipid	45#	20#
none	100	90

10

p<0.01 compared to untreated NOD mice.

15

As can be seen from Table 2, peptide treatment administered in Intralipid was effective in reducing the incidence of diabetes and death. On the other hand, treatment administered in PBS was ineffective.

Example 2.Anti-p277(Val⁶-Val¹¹) antibody production

The protection from diabetes by treatment with the p277(Val⁶-Val¹¹) peptide is dependent on TH2 immunological reactivity to the peptide. Therefore, antibody production was measured in the p277(Val⁶-Val¹¹)-immunized mice by ELISA. Maxisorp microtiter plates (Nunc) were coated with p277(Val⁶-Val¹¹) peptide, 10 µg/ml, for 18h and non-specific binding blocked with 7% milk powder for 2h. The mouse sera, diluted 1:50, were allowed to bind for 2h and the specific binding was detected by adding alkaline phosphatase anti-mouse IgG (Serotec) for 2h and p-nitrophenylphosphate substrate (Sigma) for 30 min. The color intensity was measured by an ELISA reader (Anthos) at OD=405 nm.

As can be seen from Fig 1, NOD mice immunized to p277(Val⁶-Val¹¹) in Intralipid developed peptide specific antibodies, while mice immunized to p277(Val⁶-Val¹¹) in PBS showed no antibody responses at all.

35

Example 3.Antibody isotypes induced by p277(Val⁶-Val¹¹) therapy

The association of p277(Val⁶-Val¹¹) Intralipid therapy with antibodies to p277(Val⁶-Val¹¹) shown in Example 2, 5 suggested that the therapeutic effect might result from a shift in the predominant cytokines produced by the autoimmune T cells. T cells of the CD4 "helper" type have been divided into two groups by the characteristic cytokines they secrete when activated (Mosmann and Coffman, 1989): TH1 cells secrete IL-2, 10 which induces T-cell proliferation, and cytokines such as IFN γ , which mediate tissue inflammation; TH2 cells, in contrast, secrete IL-4, which "helps" B cells produce certain antibody isotypes, and IL-10 and other cytokines, which can "depress" tissue inflammation. The possibility of a shift 15 from TH1 to TH2-like behavior was supported by analysis of the isotypes of the antibodies produced after p277(Val⁶-Val¹¹) therapy.

Groups of NOD mice, 3 months old, were treated with p277(Val⁶-Val¹¹) or with PBS in oil as described in Example 2. 20 The sera of individual mice were assayed for the isotypes of their antibodies to p277(Val⁶-Val¹¹) after treatment (12-15 mice per group). The antibody isotypes were detected using an ELISA assay with isotype-specific developing antibody reagents (Southern Biotechnology Associates, Birmingham, AL). The 25 results are shown in Fig. 2, wherein: Antibodies to p277(Val⁶-Val¹¹) in control-treated NOD mice - open circles; in p277(Val⁶-Val¹¹)-treated mice - closed circles. The columns in each experiment show results from equal numbers of mice; an apparent reduction in numbers of circles is caused by superimposition.

30 Analysis of the antibody isotypes of the anti-p277 antibodies developing after treatment showed them to be exclusively of the IgG1 and IgG2b classes, dependent on TH2 T cells producing IL-4 (Snapper et al., 1993a) and possibly TGF β (Snapper et al., 1993b). There were no TH1-type IgG2a 35 antibodies induced by p277(Val⁶-Val¹¹) therapy. The development of antibodies to the specific peptide used in treatment is a sign that the autoimmune T-cell responses have

shifted from a damaging inflammatory mode called TH1 to a TH2 T-cell response that produces innocuous antibodies and suppresses inflammation and tissue damage (Rabinovitch, 1994).

5 Example 4.

Peptide p277(Val⁶-Val¹¹)/Intralipid therapy induces a specific switch in the cytokine profile

10 To confirm the idea of a cytokine switch, the cytokines produced by the T cells reactive to the p277(Val⁶-Val¹¹) in the p277(Val⁶-Val¹¹)/Intralipid-treated and control mice were assayed. Concanavalin A (ConA), a T-cell mitogen, was used to activate total splenic T-cells as a control.

15 Groups of 10 NOD mice, 3 months old, were treated with p277(Val⁶-Val¹¹) in Intralipid (closed bars) or with PBS in Intralipid (open bars; see Example 2). Five weeks later, the spleens of the mice were removed and the spleen cells were pooled. The spleen cells were incubated with Con A or p277(Val⁶-Val¹¹) for 24h (for IL-2 and IL-4 secretion) or for 20 48h (for IL-10 and IFN γ secretion). The presence of the cytokines in the culture supernatants was quantitated by ELISA, using Pharmingen paired antibodies according to the Pharmingen cytokine ELISA protocol. Pharmingen recombinant mouse cytokines were used as standards for calibration curves. Briefly, flat-bottom 96-well microtiter plates were coated with 25 rat anti-mouse cytokine mAbs for 18h at 4°C, and the culture supernatants or recombinant mouse cytokines were added for 18h at 4°C. The plates were washed, and biotinylated rat anti-mouse cytokine mAbs were added for 45 min at room temperature, then extensively washed, and avidin-alkaline phosphatase was 30 added. The plates were washed, a chromogen substrate (p-nitrophenylphosphate) was added and samples were read at 405nm in an ELISA reader. The results are shown in Fig. 3. The concentrations of cytokines are shown as the OD readings.

*P<0.01.

35 Fig. 3A shows that the spleen cells of control mice secreted both IL-2 and IFN γ upon incubation with p277(Val⁶-Val¹¹). In contrast, the p277(Val⁶-Val¹¹)-treated mice

produced significantly less ($P<0.01$) IL-2 and IFN γ in response to incubation with peptide p277(Val 6 -Val 11). This reduction in TH1 cytokines was specific; the p277(Val 6 -Val 11)-treated mice maintained their IL-2 and IFN γ cytokine responses to ConA (Fig. 3B). Figs. 3A and 3B show the amounts of IL-10 and IL-4 produced by the spleen cells of the mice. The control mice produced very little IL-4 or IL-10 in response to p277(Val 6 -Val 11) or Con A. In contrast, there was a significant increase in IL-10 and IL-4 in response only to p277(Val 6 -Val 11) and only in the p277(Val 6 -Val 11)/Intralipid-treated mice ($P<0.01$). A decrease in IL-2 and IFN γ coupled with an increase in IL-10 and IL-4 confirms the shift from TH1-like behavior to TH2-like behavior. Such a shift might help explain both a decline in T-cell proliferation to p277 shown previously by the inventors (Elias et al., 1991) and the appearance of IgG1 and IgG2b antibodies to p277(Val 6 -Val 11) according to the present invention.

Example 5.

Spontaneous T-cell proliferative responses to p277(Val 6 -Val 11) is reduced by p277(Val 6 -Val 11) therapy

Groups of 5 female mice of the NOD/Lt strain were treated at the age of 3 months with 100 μ g of peptide p277(Val 6 -Val 11) in Intralipid or with PBS mixed with Intralipid, sc in the back. Five weeks later, the spleens of the mice were removed and the T-cell proliferative responses were assayed *in vitro* to the T-cell mitogen Con A (1.25 μ g/ml) or to p277(Val 6 -Val 11) (10 μ g/ml) using a standard assay. The results are shown in Fig. 4, wherein: Con A-black striped bars; p277(Val 6 -Val 11) - grey bars. The T-cell responses were detected by the incorporation of [3 H] thymidine added to the wells in quadruplicate cultures for the last 18 hours of a 3-day culture. The stimulation index (SI) was computed as the ratio of the mean cpm of test cultures to the mean cpm of antigen-containing wells to control wells cultured without antigens or Con A. The standard deviations from the mean cpm were always less than 10%.

As shown in Fig. 4, the control mice tested with PBS/Intralipid showed T-cell proliferative responses to both p277(Val⁶-Val¹¹) and to the T-cell mitogen Con A. In contrast, the mice treated with p277(Val⁶-Val¹¹) in Intralipid showed a decrease in T-cell proliferative reactivity to p277(Val⁶-Val¹¹) but no decrease to Con A. Thus the beneficial effect of p277(Val⁶-Val¹¹) peptide therapy is caused not by inactivating the autoimmune response, but by activating the autoimmunity into a different cytokine mode of behavior (Cohen, 1995).

Regulation of destructive autoimmunity is programmed within the immune system (Cohen, 1992); it need only be activated by a suitable signal which requires the peptide together with the lipid vehicle; neither the peptide alone or the lipid without the peptide are effective, as shown in Table 1. These results indicate that metabolizable lipid emulsions may be used defectively as vehicles for therapy of autoimmune diseases. Each disease will require its own specific peptide, but the metabolizable lipid emulsion can be used for the various therapies.

20

Example 6.

Administration of peptide in Intralipid affects development of experimental autoimmune encephalomyelitis

Experimental autoimmune encephalomyelitis (EAE) is an experimental autoimmune disease of animals that is thought to model aspects of multiple sclerosis (Zamvil and Steinman, 1990). EAE can be induced in susceptible strains of rats, such as the Lewis rat, by immunization to myelin basic protein (MBP) in complete Freund's adjuvant (CFA), an emulsion of mineral oil containing killed Mycobacteria. The disease develops about 12 days after immunization and is characterized by paralysis of various degrees due to inflammation of the central nervous system. The paralysis can last up to 6 or 7 days and the rats usually recover unless they die during the peak of their acute paralysis. EAE is caused by T cells that recognize defined determinants of the MBP molecule. The major MBP determinant in

the Lewis rat is composed of the peptide sequence 71-90 (Zamvil and Steinman, 1990).

We therefore performed an experiment to test whether administration of the encephalitogenic MBP peptide p71-90 in IFA could also inhibit the development of EAE. Fig. 5 shows that the administration of p71-90 in IFA 14 days before the induction of EAE led to a significant decrease in the maximal degree of paralysis compared to the control treatment with PBS emulsified in IFA, which had no effect on the severity of the disease. Thus, p71-90 given in IFA affects EAE.

However, IFA cannot be administered, as stated above, to humans because it is not metabolizable in the body and causes local inflammation. We therefore treated Lewis rats with p71-90 in Intralipid. Figure 6 shows the results. The rats that had received p71-90 in Intralipid developed significantly less paralysis than did the control rats treated with PBS/Intralipid. Therefore, it can be concluded that a relevant peptide such as p71-90 administered in Intralipid is capable of modulating EAE in rats. Hence, the effects of peptide/Intralipid treatment are not limited to only one peptide, in one species, or to only one autoimmune disease.

Example 7

Effectiveness of new vs. aged 10% Intralipid emulsion

10% Intralipid emulsion was used to treat 12 week old NOD female mice with p277(Val⁶-Val¹¹). The emulsion was used either on the day the sealed bottle was opened, or 4 months later, after exposure to atmospheric air. The pH of the emulsion was tested at the time of preparing the peptide+emulsion for treatment. Aging was marked by a fall in pH from 8.2 to 6.7. In each experiment 10 mice were treated with the peptide+emulsion preparation, 10 mice received the emulsion alone, and 10 mice were untreated. The results are shown in Table 3.

Table 3

5	Group	Treatment	Emulsion	Diabetes	Mortality
			pH	(%)	(%)
	1	peptide+emulsion	8.2	20*	10*
	2	emulsion	"	90	70
	3	peptide+emulsion	6.7	60	40
	4	emulsion	"	80	60
	5	untreated	-	90	80

* p < 0.01

10

It can be seen that the placebo-treated mice (emulsion only, groups 2 and 4) and the untreated mice (group 5) developed a similar incidence of diabetes, 80-90% at 6 months of age. In contrast, treating the mice with peptide in 15 the newly opened emulsion protected 80% of the mice from diabetes. However, using the "aged" emulsion only protected 40%. Therefore, the emulsion was chemically unstable after exposure to air, as shown by the marked decrease in pH value. This change is relevant to its biological activity. Hence, the 20 Intralipid is a biologically active carrier whose functional properties depend on the pH and not only on the presence of inert lipid.

Having now fully described this invention, it will be 25 appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

30 While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is intended to cover any variations, uses, or adaptations of the inventions following, in general, the principles of the 35 invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied

to the essential features hereinbefore set forth as follows in the scope of the appended claims.

All references cited herein, including journal articles or abstracts, published or unpublished U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

Reference to known method steps, conventional methods steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present application. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.

REFERENCES

1. Allegretta, M., Nicklas, J.A., Sriram, S. and Albertini, R.J., *Science* 247:718-721 (1990).
2. Banchereau, J. and Rybak, M.E., in: *The Cytokine Handbook*, 2nd Ed., A, Thompson Ed. Academic Press New York, pp 99 (1994).
3. Cohen, I.R., *Immunology Today* 13:490-494 (1992).
4. Cohen, I.R., in: *Selective Immunosuppression: Basic Concepts and Clinical Applications* (Eds. Adorini, L., Capra, D.J., Waldmann, H.) *Chem. Immunol Karger*, Basel, 60:150-60 (1995).
5. Kristiansen, T., Sparrman, M. and Heller, L., *J. Biosci* 5 (suppl. 1):149-155 (1983).
6. Liblau, R.S., Singer, S.M. and McDevitt, H.O., *Immunology Today* 16:34 38 (1995).
7. Moore, K.V., O'Garra, A., de Waal Malefyt, R., Vieira, P. and Mosmann, T.R., *Ann. Rev. Immunol.* 11:165-190 (1993).
8. Mosmann, T.R. and Coffman R.L., *Ann. Rev Immunol.* 7:145-173 (1989).
9. Ota, K., Matsui, M., Milford, E.L., Mackin, G.A., Weiner, H.I. and Hafler, D.A., *Nature* 346:183-187 (1990).
10. Rabinovitch, A., Sorensen, O., Sua-Pinzon, W.K., Rajotta, R.V. and Bleakley, R.C., *Diabetologia* 37:833-837 (1994).
11. Romagnani, S., *Ann. Rev. Immunol.* 12:227-257 (1994).
12. Snapper, C.M. and Mond, J.J., *Immunology Today* 14:15-17 (1993).
13. Snapper, C.M., Waegell, W., Beernink, H. and Dasch, J.R., *J. Immunol.* 151:4625-36 (1993).
14. Zarnvil, S.S. and Steinman, L., *Ann. Rev. Immunol.* 8:579-621 (1990).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: YEDA RESEARCH & DEVELOPMENT CO. LTD. at the Weizmann Institute of Science

(B) STREET: P.O. Box 95

(C) CITY: Rehovot

(E) COUNTRY: Israel

(F) POSTAL CODE (ZIP): 76100

(G) TELEPHONE: 972-8-470739

(H) TELEFAX: 972-8-4706178

(A) NAME: Irun R. COHEN

(B) STREET: 11 Hankin Street

(C) CITY: Rehovot

(E) COUNTRY: Israel

(F) POSTAL CODE (ZIP): 76344

(A) NAME: Dana ELIAS

(B) STREET: 57 Derech Yavne

(C) CITY: Rehovot

(E) COUNTRY: Israel

(F) POSTAL CODE (ZIP): 76344

(A) NAME: Meir SHINITZKY

(B) STREET: 20 Derech Haganim

(C) CITY: Kfar Shmaryahu

(E) COUNTRY: Israel

(F) POSTAL CODE (ZIP): 46910

(ii) TITLE OF INVENTION: PREPARATIONS AND METHODS FOR THE TREATMENT OF
T CELL MEDIATED DISEASES

(iii) NUMBER OF SEQUENCES: 4

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: IL 114458

(B) FILING DATE: 05-JUL-1995

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 573 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Met	Leu	Arg	Leu	Pro	Thr	Val	Phe	Arg	Gln	Met	Arg	Pro	Val	Ser	Arg
1										10					15

Val	Leu	Ala	Pro	His	Leu	Thr	Arg	Ala	Tyr	Ala	Lys	Asp	Val	Lys	Phe
					20				25					30	

Gly Ala Asp Ala Arg Ala Leu Met Leu Gln Gly Val Asp Leu Leu Ala
 35 40 45
 Asp Ala Val Ala Val Thr Met Gly Pro Lys Gly Arg Thr Val Ile Ile
 50 55 60
 Glu Gln Gly Trp Gly Ser Pro Lys Val Thr Lys Asp Gly Val Thr Val
 65 70 75 80
Ala Lys Ser Ile Asp Leu Lys Asp Lys Tyr Lys Asn Ile Gly Ala Lys
85 90 95
 Leu Val Gln Asp Val Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly
 100 105 110
 Thr Thr Thr Ala Thr Val Leu Ala Arg Ser Ile Ala Lys Glu Gly Phe
 115 120 125
 Glu Lys Ile Ser Lys Gly Ala Asn Pro Val Glu Ile Arg Arg Gly Val
 130 135 140
 Met Leu Ala Val Asp Ala Val Ile Ala Glu Leu Lys Lys Gln Ser Lys
 145 150 155 160
 Pro Val Thr Thr Pro Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala
 165 170 175
 Asn Gly Asp Lys Glu Ile Gly Asn Ile Ile Ser Asp Ala Met Lys Lys
 180 185 190
 Val Gly Arg Lys Gly Val Ile Thr Val Lys Asp Gly Lys Thr Leu Asn
 195 200 205
 Asp Glu Leu Glu Ile Ile Glu Gly Met Lys Phe Asp Arg Gly Tyr Ile
 210 215 220
 Ser Pro Tyr Phe Ile Asn Thr Ser Lys Gly Gln Lys Cys Glu Phe Gln
 225 230 235 240
 Asp Ala Tyr Val Leu Leu Ser Glu Lys Lys Ile Ser Ser Ile Gln Ser
 245 250 255
 Ile Val Pro Ala Leu Glu Ile Ala Asn Ala His Arg Lys Pro Leu Val
 260 265 270
 Ile Ile Ala Glu Asp Val Asp Gly Glu Ala Leu Ser Thr Leu Val Leu
 275 280 285
 Asn Arg Leu Lys Val Gly Leu Gln Val Val Ala Val Lys Ala Pro Gly
 290 295 300
 Phe Gly Asp Asn Arg Lys Asn Gln Leu Lys Asp Met Ala Ile Ala Thr
 305 310 315 320
 Gly Gly Ala Val Phe Gly Glu Glu Gly Leu Thr Leu Asn Leu Glu Asp
 325 330 335
 Val Gln Pro His Asp Leu Gly Lys Val Gly Glu Val Ile Val Thr Lys
 340 345 350
 Asp Asp Ala Met Leu Leu Lys Gly Lys Gly Asp Lys Ala Gln Ile Glu
 355 360 365
 Lys Arg Ile Gln Glu Ile Ile Glu Gln Leu Asp Val Thr Thr Ser Glu
 370 375 380
 Tyr Glu Lys Glu Lys Leu Asn Glu Arg Leu Ala Lys Leu Ser Asp Gly

385	390	395	400
Val Ala Val Leu Lys Val Gly Gly Thr Ser Asp Val Glu Val Asn Glu			
405		410	415
Lys Lys Asp Arg Val Thr Asp Ala Leu Asn Ala Thr Arg Ala Ala Val			
420	425		430
Glu Glu Gly Ile Val Leu Gly Gly Cys Ala Leu Leu Arg Cys Ile			
435	440	445	
Pro Ala Leu Asp Ser Leu Thr Pro Ala Asn Glu Asp Gln Lys Ile Gly			
450	455	460	
Ile Glu Ile Ile Lys Arg Thr Leu Lys Ile Pro Ala Met Thr Ile Ala			
465	470	475	480
Lys Asn Ala Gly Val Glu Gly Ser Leu Ile Val Glu Lys Ile Met Gln			
485	490		495
Ser Ser Ser Glu Val Gly Tyr Asp Ala Met Ala Gly Asp Phe Val Asn			
500	505		510
Met Val Glu Lys Gly Ile Ile Asp Pro Thr Lys Val Val Arg Thr Ala			
515	520		525
Leu Leu Asp Ala Ala Gly Val Ala Ser Leu Leu Thr Thr Ala Glu Val			
530	535		540
Val Val Thr Glu Ile Pro Lys Glu Glu Lys Asp Pro Gly Met Gly Ala			
545	550	555	560
Met Gly Gly Met Gly Gly Met Gly Gly Met Phe			
565	570		

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Val	Leu	Gly	Gly	Val	Ala	Leu	Leu	Arg	Cys	Ile	Pro	Ala	Leu	Asp
1				5			10			15				
Ser Leu Thr Pro Ala Asn Glu Asp														
20														

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Val Leu Gly Gly Cys Ala Leu Leu Arg Val Ile Pro Ala Leu Asp
1 5 10 15

Ser Leu Thr Pro Ala Asn Glu Asp
20

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Val Leu Gly Gly Val Ala Leu Leu Arg Val Ile Pro Ala Leu Asp
1 5 10 15

Ser Leu Thr Pro Ala Asn Glu Asp
20

CLAIMS:

1. A therapeutic preparation for treatment of a T cell mediated disease or condition comprising an antigen and a biologically active carrier, wherein the antigen is an antigen recognized by inflammatory T cells associated with the pathogenesis of said disease or condition, and wherein the said carrier is a fat emulsion comprising 10-20% triglycerides of plant and/or animal origin, 1.2-2.4% phospholipids of plant and/or animal origin, 2.25-4.5% osmo-regulator, 0-0.05% anti-oxidant, and sterile water to complete 100 ml.
2. A preparation according to claim 1, wherein the triglycerides are of plant origin.
3. A preparation according to claim 2, wherein the triglycerides are derived from soybean oil.
4. A preparation according to claim 1, wherein the triglycerides are of animal origin.
5. A preparation according to claim 4, wherein the triglycerides are derived from egg yolk or bovine serum.
6. A preparation according to any one of claims 1 to 5, wherein the phospholipids are of plant origin.
7. A preparation according to claim 6, wherein the phospholipids are derived from soybeans.
8. A preparation according to any one of claims 1 to 5, wherein the phospholipids are of animal origin.
9. A preparation according to claim 8, wherein the phospholipids are derived from egg yolk or bovine serum
10. A preparation according to any one of claims 1 to 5, wherein the osmo-regulator is selected from the group comprising glycerol, sorbitol and xylitol.
11. A preparation according to any one of claims 1 to 5, comprising 0.05% tocopherol as anti-oxidant.
12. A preparation according to claim 1, wherein the biologically active carrier is a fat emulsion comprising 10% soybean oil, 1.2% egg-yolk phospholipids, 2.5% glycerol and sterile water to complete 100 ml.
13. A preparation according to claim 1, wherein the biologically active carrier is a fat emulsion comprising 20%

soybean oil, 2.4% egg-yolk phospholipids, 2.5% glycerol and sterile water to complete 100 ml.

14. A preparation according to claim 1, wherein the biologically active carrier is a fat emulsion comprising 5% soybean oil, 5% medium chain triglycerides, 1.2% egg-yolk lecithin, 2.5% glycerol and sterile water to complete 100 ml.

15. A preparation according to any one of claims 1 to 5 or 12 to 14 which causes shifting of an individual's T-cell cytokine response from TH1 to TH2.

16. A preparation according to any one of claims 1 to 5 or 12 to 14 which causes a decrease in IL-2 or IFN- γ T-cell cytokine response and an increase in IL-4 or IL-10 T-cell cytokine response.

17. A preparation according to any one of claims 1 to 5 or 12 to 14 for the treatment of insulin dependent diabetes mellitus (IDDM) comprising a peptide derived from the human heat shock protein 60 (hsp60) that is recognized by inflammatory T-cells associated with the pathogenesis of IDDM wherein said peptide is selected from the group of peptides listed in Table 1.

18. A preparation according to claim 17 for the treatment of IDDM comprising the peptide p277 and of a fat emulsion comprising 10% soybean oil, 1.2% egg-yolk phospholipids, 2.5% glycerol and sterile water to complete 100 ml.

19. A preparation according to claim 17 for the treatment of IDDM comprising the peptide p277(Val⁶-Val¹¹) and a carrier consisting of a fat emulsion comprising 10% soybean oil, 1.2% egg-yolk phospholipids, 2.5% glycerol and sterile water to complete 100 ml.

20. A preparation according to any one of claims 1 to 5 or 12 to 14 for the treatment of multiple sclerosis comprising a peptide derived from myelin basic protein (MBP) that is recognized by T-cells involved in the pathogenesis of multiple sclerosis.

21. Use of a fat emulsion comprising 10-20% triglycerides of plant and/or animal origin, 1.2-2.4% phospholipids of plant and/or animal origin, 2.25-4.5% osmo-regulator, 0-0.05% anti-oxidant, and sterile water to complete

100 ml for the manufacture of a therapeutic preparation according to claim 1.

22. Use of a fat emulsion comprising 10% soybean oil, 1.2% egg-yolk phospholipids, 2.5% glycerol, and sterile water to complete 100 ml, for the manufacture of a therapeutic preparation according to claim 12.

23. A method of treatment of a patient suffering from a T cell mediated disease or condition which comprises administering to said patient a preparation comprising an antigen recognized by inflammatory T cells associated with the pathogenesis of said disease or condition in a biologically active carrier consisting of a fat emulsion comprising 10-20% triglycerides of plant and/or animal origin, 1.2-2.4% phospholipids of plant and/or animal origin, 2.25-4.5% osmo-regulator, 0-0.05% anti-oxidant, and sterile water to complete 100 ml.

24. A method according to claim 23, wherein the carrier consists of fat emulsion comprising 10% soybean oil, 1.2% egg-yolk phospholipids, 2.5% glycerol, and sterile water to complete 100 ml.

25. A method in accordance with claim 23 or claim 24, wherein said T cell mediated disease is an autoimmune disease and said antigen is a peptide.

26. A method in accordance with claim 23 or claim 24, wherein said T cell mediated disease is a TH1 mediated disease.

27. A method in accordance with claim 26, wherein said autoimmune disease is an organ-specific autoimmune disease.

28. A method of treatment of a patient suffering from IDDM which comprises administering to said patient a preparation comprising one or more peptides listed in Table 1 and a biologically active carrier consisting of a fat emulsion comprising 10% soybean oil, 1.2% egg-yolk phospholipids, 2.5% glycerol, and sterile water to complete 100 ml.

29. A method according to claim 28, wherein the preparation comprises the peptide p277.

30. A method according to claim 28, wherein the preparation comprises the peptide p277(Val⁶-Val¹¹).

31. A method in accordance with claim 23 or claim 24, wherein said T cell mediated disease is a T cell mediated allergic condition and said antigen is the allergen which triggered said condition.

Figure 1: Anti-p277(V6-V11) antibodies in NOD mice




Fig 2: Treatment of NOD mice with p277(V) in Intralipid induces TH2-dependent antibodies




Fig 3A: Reduction of TH1 and elevation of TH2 cytokines after treatment with p277(V) in Intralipid




Fig 3B: No change in cytokines after treatment with p277(V) in Intralipid

ConA activated splenic T-cells




Fig 4: Treatment with p277(V) in Intralipid reduces T-cell proliferation to p277(V)




Fig 5: Treatment with p71-90 In IFA reduces the severity of EAE





Fig 6: Treatment with p71-90 In Intralipid reduces the severity of EAE



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/11373

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/127, 38/00, 45/00, 45/05, 47/00, 47/44; A01N 37/18;
US CL : 424/278.1, 283.1, 450; 514/2, 13, 14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/278.1, 283.1, 450; 514/2, 13, 14

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG, MEDLINE, DERWENT WORLD PATENT
search terms: intralipid, lipofundin, adjuvant, diabetes, multiple sclerosis, autoimmune, treat, heat shock protein,
P277

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	URBAN et al. Autoimmune T Cells: Immune Recognition of Normal and Variant Peptide Epitopes and Peptide-Based Therapy. Cell, 20 October 1989 (20-10-89), Vol. 59, pages 257-271. See entire document	1-16, 20, 23-27
Y	WO 91/15225 (BRIGHAM AND WOMEN'S HOSPITAL) 17 October 1991(17.10.91), pages 12 and 24-33.	1-16, 20, 23-27
Y	US 4,395,394 (WOLFF ET AL) 26 July 1983 (26-07-83) see entire document	1-31
Y	US 5,254,339 (B. MOREIN) 19 October 1993 (19-10-93), see entire document	1-31
Y	US 5,114,844 (COHEN ET AL) 19 May 1992 (19-05-92), see entire document	1-19, 21-28, 31

Further documents are listed in the continuation of Box C. See patent family annex.

• Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

20 SEPTEMBER 1996

Date of mailing of the international search report

15 OCT 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Faxsimile No. (703) 305-3230

Authorized officer

MARTHA T. LUBET

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US96/11373

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,474,773 A (SHINITZKY ET AL) 02 October 1984 (02.10.84), see entire document.	1-31
Y	WRAITH et al. A Role for Major Histocompatibility Complex-Binding Peptides in the Immunotherapy of Autoimmune Disease. Springer Seminars in Immunopathology 1992, Vol. 14, pages 95-101, see entire document	1-16, 20, 23-27
Y	ELIAS et al. Vaccination Against Autoimmune Mouse Diabetes with a T-cell Epitope of the Human 65-kDa Heat Shock Protein . Proc. Natl. Acad. Sci. USA. April 1991, Vol. 88, pages 3088-3091, see entire document.	1-19, 21-31
X,P	MARTIN et al. Experimental Immunotherapies for Multiple Sclerosis. Springer Semin. Immunopathol. 1996, Vol. 18, pages 1-24, see entire document.	1-31